^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    sonolisib (PX 866)

    i
    Associations
    News

    Trials

    Company:
    Pfizer
    Drug class:
    PI3K inhibitor, AKT inhibitor, PTEN inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Phase 1 and 2 Study of PX-866 and Cetuximab (NCT01252628)
    Phase 1/2
    Cascadian Therapeutics Inc.
    Completed
    Last update posted :
    05/16/2018
    Initiation :
    12/01/2010
    Primary completion :
    11/01/2013
    Completion :
    01/01/2014
    KRAS
    |
    KRAS mutation
    |
    Erbitux (cetuximab) • sonolisib (PX 866)